LIST OF CONTENTS

NUMBER 1, JANUARY 1987

Perspectives and Commentaries

M. G. Malkin and *J. B. Posner* — 1 — **Cerebrospinal fluid tumor markers for the diagnosis and management of leptomeningeal metastases**

R. A. Karmali — 5 — **Eicosanoids in breast cancer**

L. M. Weisenthal — 9 — **Clones, dyes, nuclides, mouse kidneys, and . . . virions: a new-clonogenic assay for tumor chemosensitivity**

O. Fakhri and *H. Al-Mondhiry* — 13 — **The therapeutic use of peritoneal macrophages in infected leukaemic patients**

D. Arenholt, H. P. Philipsen, H. Nikai, L. Andersen and *A. Jepsen* — 19 — **Chemically unrelated tumor promoters induce identical morphological changes in cultured rat oral epithelium**

L. Castagnetta, A. Traina, A. di Carlo, A. M. Latteri, G. Carruba and *R. E. Leake* — 31 — **Heterogeneity of soluble and nuclear oestrogen receptor status of involved nodes in relation to primary breast cancer**

V. M. Meade, M. A. Burton, B. N. Gray and *G. W. Self* — 37 — **Distribution of different sized microspheres in experimental hepatic tumours**

D. Suda, J. Schwartz and *G. Shklar* — 43 — **GGT reduction in beta carotene-inhibition of hamster buccal pouch carcinogenesis**

R. Abeie, H. P. Honegger, R. Grossenbacher, B. Mermillod, E. Kaplan, A. Gervasi, M. Wolfensberger, W. Lehmann and *F. Cavalli* — 47 — **A randomized study of methotrexate, bleomycin, hydroxyurea with versus without cisplatin in patients with previously untreated and recurrent squamous cell carcinoma of the head and neck**

E. G. E. de Vries, C. Meijer, N. H. Mulder and *P. E. Postmus* — 55 — ***In vitro* chemosensitivity of human lung cancer for vindesine**

H. G. Drexler, M. Menon, G. Gaedicke and *J. Minowada* — 61 — **Expression of FMC7 antigen and tartrate-resistant acid phosphatase isoenzyme in cases of B-lymphoproliferative diseases**

W. Lehmann, F. D. Böhmer, U. Karsten, H. Graetz, A. Koberling, D. Kunde and *P. Langen* — 69 — **Altered growth control by natural growth inhibitors in the mutant HD33 substrain of the Ehrlich–Lettré ascites mammary carcinoma**

M. E. Gore, C. A. Hills, Z. H. Siddik, J. P. Sloane, A. R. Winkley, I. E. Smith and *J. L. Millar* — 75 — **Priming reduces the bone marrow toxicity of carboplatin**

S. Djilali, A.-L. Parodi and *D. Levy* — 81 — **Bovine leukemia virus replicates in sheep B lymphocytes under a T cell released factor**

P. K. Buamah, C. Cornell, C. W. Venables and *A. W. Skillen* — 87 — **An initial appraisal of the value of serum carbohydrate antigenic determinant (CA 19–9) levels in patients with pancreatic cancer**

D. M. Teale, J. C. E. Underwood, C. W. Potter and *R. C. Rees* — 93 — **Therapy of spontaneously metastatic HSV-2 induced hamster tumours with cortisone acetate administered with or without heparin**

F. R. Balkwill, M. H. Stevens, D. B. Griffin, J. A. Thomas and *J. G. Bodmer* — 101 — **Interferon gamma regulates HLA-D expression on solid tumors *in vivo***

Letters to the Editor

V. Kuenen-Boumeester, W. L. J. van Putten, D. I. Blonk and *M. Boon* — 107 — **Prognosis and cytomorphometry in breast cancer**

R. J. Osborne, M. L. Slevin, P. F. M. Wrigley and *C. R. Franks* — 109 — **TN06 in non small cell lung cancer**

Announcements — 111 — **International Conference: Anticancer Drugs—Therapeutic Index Improvement by Toxicity Reduction**

Progress and Controversies in Oncological Urology II

Software Survey Section — I

List of Contents

NUMBER 2, FEBRUARY 1987

Obituary	113	
Perspectives and Commentaries		
N. Clumeck	115	**The epidemic of AIDS virus infection, what is the interest for oncologists?**
G. N. Hortobagyi	119	**Is cisplatin useful for breast cancer?**
M. S. Piver	123	**Specialized surgery in ovarian cancer**
J. J. Body and *A. Borkowski*	127	**Nutrition and quality of life in cancer patients**
W. Bollag and *H.-R. Hartmann*	131	**Inhibition of rat mammary carcinogenesis by an arotinoid without a polar end group (Ro 15-0778)**
M. Kasper, P. Stosiek, H. Typlt and *U. Karsten*	137	**Histological evaluation of three new monoclonal anti-cytokeratin antibodies. 1. Normal tissues**
J. Ø. Moskaug, H. Kr. Kotlar and *T. Sanner*	149	**Cell-populations involved in the humoral leukocyte adherence inhibition reaction. The T8-suppressor/cytotoxic cells are both effectors and responders**
L. A. Noorduyn and *C. J. Herman*	157	**The relation between mixed mesodermal tumors and adenocarcinomas of the ovary. An immunopathologic study**
T. Morizane, T. Nakamura, H. Saito, T. Watanabe, Y. Inagaki, I. Satoh, K. Tsuchimoto and *M. Tsuchiya*	163	**Transformation of NIH/3T3 cells by DNA from a human hepatoma cell line with integrated hepatitis B virus DNA**
T. A. W. Splinter, E. H. Cooper, G. S. Kho, R. Oosterom and *M. D. Peake*	171	**Neuron-specific enolase as a guide to the treatment of small cell lung cancer**
H. Roed, I. J. Christensen, L. L. Vindeløv, M. Spang-Thomsen and *H. H. Hansen*	177	**Inter-experiment variation and dependence on culture conditions in assaying the chemosensitivity of human small cell lung cancer cell lines**
J. A. M. Stolwijk, F. J. A. Prop, L. Eijgenstein, F. Karten, K. Peters, M. Polak, J. Spies and *L. Souw*	187	**Representativity of human mammary tumor cell cultures: DNA-cytophotometry as a method for checking tumour cell characteristics**
J. Verwey, J. de Vries and *H. M. Pinedo*	195	**Mitomycin C-induced renal toxicity, a dose-dependent side effect?**
I. Matsui-Yuasa, S. Otani, S. Morisawa, K. Kageyama and *Y. Onoyama*	201	**Effect of hyperthermia on spermidine/spermine N^1-acetyltransferase activity in Ehrlich ascites cells**
H. Brincker, J. Hindberg and *P. V. Hansen*	205	**Cyclic alternating polychemotherapy with or without upper and lower half-body irradiation in small cell anaplastic lung cancer. A randomized study**
R. W. Stephens, C. J. Fordham and *W. F. Doe*	213	**Proenzyme to urokinase-type plasminogen activator in human colon cancer: *in vitro* inhibition by monocyte minactivin after proteolytic activation**
Y. L. Lu, H. Sobis and *M. Vandeputte*	223	**Neoplastic transformation of the rat visceral yolk sac by polyoma virus**
K. Aabo	231	**Prostate cancer: evaluation of response to treatment, response criteria, and the need for standardization of the reporting of results**
J.-P. Moulinoux, V. Quemener and *Y. Chambon*	237	**Evolution of red blood cell polyamine levels in partially hepatectomized rat**
E. J. Johnson, C. S. Scott, L. A. Parapia and *A. N. Stark*	245	**Diagnostic differentiation between reactive and malignant lymphoid cells in serous effusions**
Letter to the Editor		
S. Gundersen, R. Abele, F. Cavalli, M. Clavel, P. Dodion, G. Renard and *M. van Glabbeke*	251	**Phase II trial of triglycidylurazol (TGU) in advanced malignant melanoma**
Announcement	253	**35th Meeting of the European Tissue Culture Society (ETCS), 20–24 September 1987, Athens, Greece**
Books Received	254	
Software Survey Section	I	

List of Contents

NUMBER 3, MARCH 1987

Perspectives and Commentaries		
H. Vorherr	255	**Thyroid function in benign and malignant breast disease**
H. S. Hochster and *M. Piccart*	259	**Intraperitoneal chemotherapy: belly-bath or pain-in-the-side?**
F. R. Appelbaum and *E. D. Thomas*	263	**Bone marrow transplantation for malignant lymphoma**
P. Gaetani, V. Silvani, G. Butti, G. Spanu, A. Rossi and *R. Knerich*	267	**Nitrosourea derivatives-induced pulmonary toxicity in patients treated for malignant brain tumors. Early subclinical detection and its prevention**
Y. Maehara, H. Anai, R. Tamada and *K. Sugimachi*	273	**The ATP assay is more sensitive than the succinate dehydrogenase inhibition test for predicting cell viability**
O.-P. Kallioniemi, T. Hietanen, J. Mattila, M. Lehtinen, K. Lauslahti and *T. Koivula*	277	**Aneuploid DNA content and high S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer**
R. Somers, J. M. V. Burgers, M. Qasim, M. van Glabbeke, N. Duez and *M. Hayat*	283	**EORTC trial non-Hodgkin lymphomas**
S. R. Keyes, J. A. Hickman and *A. C. Sartorelli*	295	**The effects of adriamycin on intracellular calcium concentrations of L1210 murine leukemia cells**
K. Wassermann and *S. N. Rasmussen*	303	**Comparative responsiveness and pharmacokinetics of doxorubicin in human tumor xenografts**
V. H. C. Bramwell, H. T. Mouridsen, A. Santoro, G. Blackledge, R. Somers, J. Verwey, P. Dombernowsky, M. Onsrud, D. Thomas, R. Sylvester and *A. van Oosterom*	311	**Cyclophosphamide versus Ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas**
L. Cavanna, M. di Stasi, F. Fornari, G. Civardi, G. Sbolli, E. Buscarini and *L. Buscarini*	323	**Ultrasound and ultrasonically guided biopsy in hepatic lymphoma**
C. U. Ludwig, H.-R. Stoll, R. Obrist and *J.-P. Obrecht*	327	**Prevention of cytotoxic drug induced skin ulcers with Dimethyl Sulfoxide (DMSO) and α-Tocopherole**
P. C. Billings, R. R. Weichselbaum and *A. R. Kennedy*	331	**Expression and methylation of the Blym gene in human tumor cell lines**
Letter to the Editor		
R. S. Umans and *A. R. Kennedy*	339	**Effects of testosterone and dihydrotestosterone on malignant transformation in C3H10T½ cells**
Sounding Board		
L. Gross	343	**The concept of viral etiology of cancer and allied diseases with particular reference to cancer of the colon**
Software Survey Section	I	

NUMBER 4, APRIL 1987

Acknowledgements	347	
Perspectives and Commentaries		
G. P. Canellos	351	**The case for high-dose chemotherapy: is it chemotherapy's last gamble?**
R. Feld	357	**Quality of life in patients with non-small cell lung cancer treated with chemotherapy**
J. Folkman	361	**What is the role of angiogenesis in metastasis from cutaneous melanoma?**
O. Mella, R. Eriksen, O. Dahl and *O. D. Laerum*	365	**Acute systemic toxicity of combined *cis*-diamminedichloroplatinum and hyperthermia in the rat**
Medical Research Council Working Party on Urological Cancer, Subgroup in Advanced Bladder Cancer	375	**A phase II study of Carboplatin in metastatic transitional cell carcinoma of the bladder**

G. Masucci, H. Mellstedt, M.-G. Masucci, I. Ernberg, R. Szigeti, G. Henle, W. Henle and *G. Klein*	379	**Analysis of Epstein–Barr virus-specific and non-specific immune functions in a patient during the development of a non-Hodgkin's lymphoma**
R. Abele, M. Clavel, S. Monfardini, U. Bruntsch, J. Renard, M. van Glabbeke and *H. M. Pinedo*	387	**Phase II study of iproplatin (CHIP, JM-9) in advanced squamous cell carcinoma of the head and neck**
D. B. Smith and *A. Howell*	391	**A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer**
R. Menon, J. Bartley, S. Som and *M. R. Banerjee*	395	**Metabolism of 7,12-dimethylbenz[a]anthracene by mouse mammary cells in serum-free organ culture medium**
W. G. Peters, R. Willemze and *L. P. Colly*	401	**Preliminary results of consolidation therapy with high-dose cytosine arabinoside for patients with bad-risk or relapsed acute leukemia or lymphoblastic non-Hodgkin's lymphoma**
P. Hill and *E. L. Wynder*	407	**Comparison of mammary adipose fatty acid composition in Japanese and American breast cancer patients**
C. E. Musclow, H. Farkas-Himsley, S. S. Weitzman and *M. Herridge*	411	**Acute lymphoblastic leukemia of childhood monitored by bacteriocin and flowcytometry**
M. B. Ojeda, M. C. Alonso, R. Bastus, E. Alba, J. M. Piera and *J. J. Lopez Lopez*	419	**Follow-up of breast cancer stages I and II. An analysis of some common methods**
H. Magdelenat, C. Laine-Bidron, S. Merle and *A. Zajdela*	425	**Estrogen and progestin receptor assay in fine needle aspirates of breast cancer: methodological aspects**
M. Gasparini, C. Tondini, A. Azzarelli and *F. Fossati-Bellani*	433	**Long-term evaluation of surgery followed by adjuvant adriamycin in osteogenic sarcoma**
S. G. Pradhan, M. P. Chitnis, V. S. Basrur and *S. K. Tantri*	437	**Modulation of *in vitro* response to adriamycin by verapamil in murine P388 leukaemia, Ehrlich ascites carcinoma and sarcoma 180**
J. M. Raemaekers, L. V. Beex, G. F. Pieters, A. G. Smals, T. J. Benraad, P. W. Kloppenborg and *The Breast Cancer Study Group*	443	**Progesterone receptor activity and the response to the first endocrine therapy in advanced breast cancer**
Letter to the Editor		
P. M. Ravdin, M. van Beurden, N. F. Fritz, S. P. Robinson and *V. C. Jordan*	449	**Effect of submandibular gland removal on carcinogen induced rat mammary tumors**
Announcements	451	
Software Survey Section	I	

NUMBER 5, MAY 1987

Perspectives and Commentaries		
G. Leclercq	453	**Technical pitfalls, methodological improvements and quality control of steroid hormone receptor assays**
D. Bron and *P. Stryckmans*	459	**Role of chemotherapy for localized non-Hodgkin's lymphoma?**
J. Jansen	465	**Hairy cell leukemia still an enigmatic disease**
E. Smales and *M. J. Peckham*	469	**Chemotherapy of germ-cell ovarian tumours: first-line treatment with etoposide, bleomycin and cisplatin or carboplatin**
M. Gasparini, C. Andreoli, A. Rodari, A. Costa and *G. L. Buraggi*	475	**Lack of efficacy of lymphoscintigraphy in detecting axillary lymph node metastases from breast cancer**
N. Lena, A. M. Imbert, R. Favre, J. P. Cano and *Y. Carcassonne*	481	**Methotrexate test-dose protocol in the presence of 7-hydroxymethotrexate**
F. Levi, C. Horvarth, M. Mechkouri, A. Roulon, F. Bailleul, G. Lemaigre, A. Reinberg and *G. Mathe*	487	**Circadian time dependence of murine tolerance for the alkylating agent peptichemio**
B. Terracini, G. Pastore, M. G. Zurlo, G. Masera, F. Fossati-Bellani, M. Castello, P. Tamaro, F. Massolo, D. Rosati, P. F. Biddau and *A. Russo*	499	**Late deaths and second primary malignancies among long-term survivors of childhood cancer: an Italian multicentre study**
K. Mross, P. Maessen, W. J. F. van der Vijgh, J. F. Bogdanowicz, K. H. Kurth and *H. M. Pinedo*	505	**Absorption of epi-doxorubicin after intravesical administration in patients with *in situ* transitional cell carcinoma of the bladder**

T. Patrice, P. Jutel, M. T. Foultier, D. Cloarec, J. F. Trechot, M. C. Douet and *L. le Bodic*	509	**Photochemotherapy mediated by hematoporphyrin derivative in gastroenterology**
R. Bassan, R. Battista, B. Comotti, B. Minetti, T. Chisesi, E. Dini and *T. Barbui*	513	**Treatment of the lymphoid blast crisis of chronic myeloid leukemia**
J. Berry, B. J. Green and *D. S. Matheson*	517	**Modulation of natural killer cell activity by tamoxifen in Stage I post-menopausal breast cancer**
M. V. Pimm, J. A. Clegg and *R. W. Baldwin*	521	**Biodistribution and tumour localization of radiolabelled monoclonal antibody during continuous infusion in nude mice with human tumour xenografts**
A. Leclerc, J. Brugère, D. Luce, D. Point and *P. Guenel*	529	**Type of alcoholic beverage and cancer of the upper respiratory and digestive tract**
U. Tirelli, A. Carbone, V. Zagonel, A. Veronesi and *R. Canetta*	535	**Non-Hodgkin's lymphomas in the elderly: prospective studies with specifically devised chemotherapy regimens in 66 patients**
C. Pallares, R. Bastus, J. J. Lopez and *L. de Andres*	541	**Long-term survival in small cell carcinoma of the lung**
A.-R. Hanauske, C. K. Osborne, G. C. Chamness, G. M. Clark, B. J. Forseth, J. B. Buchok, C. L. Arteaga and *D. D. von Hoff*	545	**Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents**
B. Rasmusson, U. Feldt-Rasmussen, L. Hegedüs, H. Perrild, K. Bech and *M. Høier-Madsen*	553	**Thyroid function in patients with breast cancer**
R. Stuart-Harris, R. J. Simes, A. S. Coates, D. Raghavan, R. Devine and *M. H. N. Tattersall*	557	**Patient treatment preference in advanced breast cancer: a randomized cross-over study of doxorubicin and mitozantrone**
H. Braunsberg, N. G. Coldham, R. E. Leake, S. K. Cowan and *W. Wong*	563	**Actions of a progestogen on human breast cancer cells: mechanisms of growth stimulation and inhibition**
Letters to the Editor		
H. Braunsberg, N. G. Coldham and *R. E. Leake*	573	**Effects of serum type on steroid receptor binding sites and response to progestin of cultured human breast cancer cells**
M. Clerico, O. Bertetto, V. Dongiovanni and *A. Calciati*	577	**Phase II trial of VP16-213 in squamous cell carcinoma of the head and neck**
P. Dombernowsky, J. Buesa, H. M. Pinedo, A. Santoro, H. Mouridsen, R. Somers, V. Bramwell, M. Onsrud, J. Rouesse, D. Thomas and *R. Sylvester*	579	**VP-16 in advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma group**
G. P. M. ten Velde, L. H. Greve and *G. H. Blijham*	581	**Cisplatin and cytarabine combination chemotherapy of advanced non-small cell lung cancer: a pilot study**
Sounding Board		
M. J. Duffy	583	**Do proteases play a role in cancer invasion and metastasis?**
Announcements	591	
Books Received	593	
Software Survey Section	I	

NUMBER 6, JUNE 1987

Perspectives and Commentaries		
G. Schwartsmann and *H. M. Pinedo*	595	**Clinical trials in advanced breast cancer**
J. E. Trosko	599	**Mechanisms of tumor promotion: possible role of inhibited intercellular communication**
A.-R. Hanauske, U. Hanauske and *D. D. von Hoff*	603	**Recent improvements in the human tumor cloning assay for sensitivity testing of antineoplastic agents**
B. C. Baguley and *W. R. Wilson*	607	**Comparison of *in vivo* and *in vitro* drug sensitivities of Lewis lung carcinoma and P388 leukaemia to analogues of amsacrine**

List of Contents

F. Roile, M. Tonato, C. Basurto, V. Minotti, E. Ballatori and *A. del Favero*	615	**Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF**
D. A. L. Morgan, D. Gilson and *J. Fletcher*	619	**Vincristine and etoposide: an effective chemotherapy regimen with reduced toxicity in extensive small-cell lung cancer**
T. L. J. Boehm, H.-P. Hirth, B. Kornhuber and *D. Drahovsky*	623	**Oncogene amplifications, rearrangements, and restriction fragment length polymorphisms in human leukaemia**
M. J. Piccart, J. L. Speyer, J. C. Wernz, J. Noumoff, U. Beller, M. Beckman, N. Dubin, R. Demopoulos and *F. Muggia*	631	**Advanced ovarian cancer: three-year results of a 6–8 month, 2-drug cisplatin-containing regimen**
J. M. Esteban, J. Schlom, F. Mornex and *D. Colcher*	643	**Radioimmunotherapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: histological and autoradiographic study of effects on tumors and normal organs**
E. Galligioni, L. Canobbio, F. Figoli, T. Fassio, S. Frustaci, D. Crivellari, E. Vaccher, G. Lo Re, G. Gasparini, A. Veronesi and *S. Monfardini*	657	**Cisplatin and 5-fluorouracil combination chemotherapy in advanced and/or metastatic colorectal carcinoma: a phase II study**
A.-M. Buckle, J. R. Goepel and *R. C. Rees*	663	**The effect of the immune status of the TAR mouse on the growth and metastasis of tumour xenografts**
Y. Matsuya and *I. Yamane*	675	**Increased tumorigenicity of polyploid Ehrlich variants during growth *in vivo* is associated with karyotypic changes**
C. A. Presant, P. Multhauf and *G. Metter*	683	**Reversal of cancer chemotherapeutic resistance by amphotericin B—a broad phase I–II pilot study**
I. Norheim, E. Wilander, K. Öberg, E. Theodorsson-Norheim, M.-L. Lundqvist, P. Lindgren and *J. Bergh*	689	**Tachykinin production by carcinoid tumours in culture**
W. G. Dippold, G. Kron, E. Boosfeld, H.-P. Dienes, R. Klingel, A. Knuth, R. Wagner and *K.-H. Meyer zum Büschenfelde*	697	**Signet ring stomach cancer: morphological characterization and antigenic profile of a newly established cell line (Mz-Sto-1)**
M. Stroun, P. Anker, J. Lyautey, C. Lederrey and *P. A. Maurice*	707	**Isolation and characterization of DNA from the plasma of cancer patients**
W. Meier, P. Stieber, A. Fateh-Moghadam, W. Eiermann and *H. Hepp*	713	**CA-125 in gynecological malignancies**
L. Bruce, B. W. Hancock and *L. Cawood*	719	**Malignant lymphoma: monitoring of tumour status in 273 patients using a monoclonal antibody, 'B5', reacting with autologous erythrocytes**
M. Delhaye, B. Gulbis, N. Mairesse and *P. Galand*	723	**Characterization of γ-glutamyltransferase from neoplastic and non-neoplastic liver tissues in man and during rat liver hepatocarcinogenesis**
S. S. N. de Graaf, W. P. Meeuwsen-van der Roest, H. S. Koops and *W. G. Zijlstra*	731	**Dissociation of body weight and lean body mass during cancer chemotherapy**
G. Schwartsmann, H. M. Pinedo and *A. Leyva*	739	**Resistance of HL-60 promyelocytic leukemia cells to induction of differentiation and its reversal by combination treatment**
N. Padmanabhan, D. Y. Wang, J. W. Moore and *R. D. Rubens*	745	**Ovarian function and adjuvant chemotherapy for early breast cancer**
C. Lindemalm, H. Mellstedt, B. Nilsson, P. Biberfeld, M. Björkholm, B. Christensson, G. Holm and *B. Johansson*	749	**Blood clonal B cell excess (CBE) at diagnosis in patients with non-Hodgkin lymphoma (NHL). Relation to clinical stage, histopathology and response to treatment**
L. Vlatkovic, A. E. Lykkesfeldt, K. Hou-Jensen and *P. Briand*	755	**Comparison of the immunocytochemical assay (ER-ICA) and the biochemical assay for estrogen receptor in human breast cancer cell lines**
A. Khar and *A. M. Ali*	761	**Serum protects HeLa cells from antiestrogen effects in culture**
S. K. Khoo, T. Hurst, M. J. Webb, G. J. Dickie, J. H. Kearsley and *E. V. Mackay*	765	**Predictive value of serial CA 125 antigen levels in ovarian cancer evaluated by second-look laparotomy**
M. Iigo, Y. Nakajima, A. Hoshi and *E. de Clercq*	773	**Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil and ftorafur against adenocarcinoma 755 in mice**

H. S. Thomsen, D. Rasmussen, O. Munck, J. O. Lund, V. Gerhard-Nielsen, T. Terkildsen, P. Dombernowsky and *K. W. Andersen*	779	**Bone metastases in primary operable breast cancer. The role of a yearly scintigraphy**
R. Lewensohn, J. Hansson, U. Ringborg and *H. Ehrsson*	783	**Differential DNA cross-linking and cytotoxicity in PHA-stimulated human lymphocytes exposed to melphalan, *m*-L-sarcolysin and peptichemio**
D. Tait, V. R. McCready and *R. J. Ott*	789	**HM-PAO assessment of human tumour perfusion**
N. Cascinelli, M. Greco, R. Bufalino, C. Clemente, D. Galluzzo, V. delle Donne, R. de Lellis, V. Sacchini and *U. Veronesi*	795	**Prognosis of breast cancer with axillary node metastases after surgical treatment only**
T. J. McMillan, T. C. Stephens, J. H. Peacock and *G. G. Steel*	801	**Development of MeCCNU-resistance in clonally derived lines of Lewis lung carcinoma**
J. van Hoogenhuijze, J. Lankelma, J. Stam and *H. M. Pinedo*	807	**Unchanged pharmacokinetics of VP-16-213 (etoposide, NSC 141540) during concomitant administration of doxorubicin and cyclophosphamide**
S. E. Dible, Z. H. Siddik, F. E. Boxall and *K. R. Harrap*	813	**The effect of diethyldithiocarbamate on the haematological toxicity and antitumour activity of carboplatin**
B. G. Mobbs, E. B. Fish, K. I. Pritchard, G. Oldfield and *W. H. Hanna*	819	**Estrogen and progesterone receptor content of primary and secondary breast carcinoma: influence of time and treatment**
P. Boyle, S. B. Kaye and *A. G. Robertson*	827	**Changes in testicular cancer in Scotland**
R. G. Fish, M. D. Shelley, T. Maughan, I. Rocker and *M. Adams*	831	**The clinical value of serum CA125 levels in ovarian cancer patients receiving platinum therapy**
P. F. Dodion, J. Abrams, B. Gérard, N. Crespeigne, B. Peeters, C. van Berchem and *Y. Kenis*	837	**Clinical and pharmacokinetic phase I trial with the diethylaminoester of flavone acetic acid (LM985, NSC 293015)**
A. Thyss, G. Milano, A. Deville, J. Manassero, N. Renee and *M. Schneider*	843	**Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies**
P. Gaglia, R. Bussone, B. Caldarola, M. Lai, A. Jayme and *L. Caldarola*	849	**The correlation between the spread of metastases by level in the axillary nodes and disease-free survival in breast cancer. A multifactorial analysis**
T. E. Wheldon, I. Berry, J. A. O'Donoghue, A. Gregor, I. M. Hann, A. Livingstone, J. Russell and *L. Wilson*	855	**The effect on human neuroblastoma spheroids of fractionated radiation regimes calculated to be equivalent for damage to late responding normal tissues**
I. Lasnitzki and *W. Bollag*	861	**Prevention and reversal by a non-polar arotinoid (Ro 15-0778) of 3,4-benzpyrene- and cigarette smoke condensate-induced hyperplasia and metaplasia of rodent respiratory epithelia grown *in vitro***
M. George, V. Scotto, F. Carnino, P. Dodion, W. W. ten Bokkel Huinink, N. Rotmensz and *J. B. Vermorken*	867	**Phase II trial of anaxirone (1,2,4-triglycidylurazol, TGU) in patients with advanced ovarian carcinoma: an EORTC Gynecological Cancer Cooperative Group study**
Letters to the Editor		
T. L. J. Boehm and *D. Drahovsky*	871	**Oncogene amplification and clonal evolution in acute leukaemia**
S. D. Fossa	875	**Improved subjective tolerability of interferon by combination with prednisolone**
Special Articles		
L. E. Reinstein, A. S. Glicksman and *F. Laurie*	877	**Technical structure of a radiotherapy protocol**
G. B. Snow, N. de Vries, N. van Zandwijk and *H. M. Pinedo*	883	**Second primary cancers in the lung in head and neck cancer patients: a challenge**
J. F. Smyth, F. R. Balkwill, F. Cavalli, A. Kimchi, K. Mattson, N. E. Niederle and *R. J. Spiegel*	887	**Interferons in oncology: current status and future directions**
Announcements	891	
Erratum	892	
Software Survey Section	I	

List of Contents

NUMBER 7, JULY 1987

Perspectives and Commentaries

R. A. Stahel and *G. Martz* 893 **Prognostic and diagnostic usefulness of serum markers in lung cancer**

M. Buyse and *H. Bleiberg* 895 **Counting and sampling errors: (mis)interpretation of data from tritiated thymidine labelled human tumors**

N. E. Davidson and *M. E. Lippman* 897 **Stimulation of breast cancer with estrogens: how much clinical value?**

R. Madiyalakan, C. F. Piskorz, M. S. Piver and *K. L. Matta* 901 **Serum β-(1 → 4)-galactosyltransferase activity with synthetic low molecular weight acceptor in human ovarian cancer**

R. Danesi, M. del Tacca, C. Bernardini and *S. Penco* 907 **Exogenous doxorubicinol induces cardiotoxic effects in rats**

A. Jakobsen, K. Bertelsen and *A. Sell* 915 **Cyclic hormonal treatment in ovarian cancer. A phase-II trial**

M.-C. Martyre, R. Beaupain and *E. Falcoff* 917 **Potentiation of antiproliferative activity by mixtures of human recombinant IFN-α2 and -γ on growth of human cancer nodules maintained in continuous organotypic culture**

M. Prat, B. Griselli, A. Bernardi, P. Rossino, G. L. Candelaresi, A. P. Cappa and *P. M. Comoglio* 923 **Expression of the monoclonal antibody-defined CAR-3 epitope on neoplastic and preneoplastic lesions of the colon mucosa**

I. C. Shaw and *M. S. Weeks* 933 **Excretion of disodium *bis*-2-mercaptoethanesulphonate (dimesna) in the urine of volunteers after oral dosing**

H. H. Fiebig, J. R. Schmid, W. Bieser, H. Henss and *G. W. Lohr* 937 **Colony assay with human tumor xenografts, murine tumors and human bone marrow. Potential for anticancer drug development**

P. Lissoni, A. Bastone, R. Sala, R. Mauri, F. Rovelli, S. Viviani, E. Bajetta, D. Esposti, G. Esposti, L. di Bella and *F. Fraschini* 949 **The clinical significance of melatonin serum determination in oncological patients and its correlations with GH and PRL blood levels**

L. Tabar, S. W. Duffy, and *U. B. Krusemo* 959 **Detection method, tumour size and node metastases in breast cancers diagnosed during a trial of breast cancer screening**

A. A. Hakim 963 **Ulcerative colitis and familial polyposis oncologic transformation to colon carcinoma: changes in carcinoembryonic antigen release**

C. Sauter and *M. Cogoli* 973 **Tetracycline in the treatment of malignant effusions: evidence for a cytostatic action of the decomposed drug**

D. B. Smith, A. Howell and *J. Wagstaff* 979 **Infiltrating lobular carcinoma of the breast: response to endocrine therapy and survival**

A. Twijnstra, P. J. Boon, A. C. M. Lormans and *G. P. M. ten Velde* 983 **Neurotoxicity of prophylactic cranial irradiation in patients with small cell carcinoma of the lung**

B. K. Olesen, P. Ernst, M. H. Nissen and *H. H. Hansen* 987 **Recombinant interferon A (IFL-rA) therapy of small cell and squamous cell carcinoma of the lung. A phase II study**

S. S. Ottesen, J. Kieler and *B. Christensen* 991 **Changes in HLA A, B, C expression during "spontaneous" transformation of human urothelial cells *in vitro***

M. E. L. van der Burg, W. W. ten Bokkel Huinink, R. Vriesendorp, A. T. van Oosterom, J. P. Neijt, J. B. Vermorken, W. L. J. van Putten and *A. Kooiman* 997 **Teniposide (VM-26) in patients with advanced refractory ovarian cancer: a phase II study of The Netherlands Joint Study Group for Ovarian Cancer**

B. W. Borjesson, R. McGinley, T. M. S. Foo, C. Smyth, M. Toppila, P. Compton and *G. A. Sarfaty* 999 **Estrogen and progesterone receptor assays in human breast cancer: sources of variation between laboratories**

M. R. Schneider, E. von Angerer, W. Höhn and *F. Sinowatz* 1005 **Antitumor activity of antiestrogenic phenylindoles on experimental prostate tumors**

J. Wils, H. Bleiberg, O. Dalesio, N. Duez, G. Blijham, A. Planting, T. Splinter and *W. Weber* 1017 **An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with 5-fluorouracil in advanced adenocarcinoma of the pancreas**

H. Nagasawa and *R. Konishi*	1019	**Precancerous mammary hyperplastic alveolar nodules in four strains of virgin mice with different mammary tumor potentials: influence of chronic caffeine ingestion**
F. Levi, C. la Vecchia and *A. Decarli*	1025	**Cigarette smoking and the risk of endometrial cancer**
B. Lund, F. Hansen, M. Hansen and *H. H. Hansen*	1031	**Phase II study of 1,2,4-triglycidylurazol (TGU) in previously untreated and treated patients with small cell lung cancer**
B. Marian	1035	**Tumor-promoting phorbol esters cause a stable reduction of dermal collagen in mouse skin**
G. Lambertenghi-Deliliers, A. T. Maiolo, C. Annaloro, A. Cortelezzi, E. Pogliani, F. Ganzina and *E. E. Polli*	1041	**Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute non-lymphoblastic leukemia**
L.-M. Ching and *B. C. Baguley*	1047	**Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347 512)**
E. Kovacs and *A. Almendral*	1051	**Reduced DNA repair synthesis in healthy women having first degree relatives with breast cancer**
M. Iigo, Z. Yamaizumi, S. Nishimura and *A. Hoshi*	1059	**Mechanism of potentiation of antitumor activity of 5-fluorouracil by guanine ribonucleotides against adenocarcinoma 755**
R. K. Severson and *S. Davis*	1067	**Breast cancer incidence and month of birth: evidence against an etiologic association**
F. G. Lawton, K. A. Kelly, L. J. Sant Cassia and *G. Blackledge*	1071	**Speed of response to platinum-based chemotherapy: implications for the management of epithelial ovarian cancer**
Letters to the Editor		
G. Zavagno, D. Nitti, A. Marchet N. Moschin, C. Belluco, F. de Marchi, F. Serafini and *M. Lise*	1077	**Significance of serum ferritin in patients with gastric and colorectal cancer**
E. M. Rankin, R. K. Knight and *R. D. Rubens*	1079	**A phase II study of 4-deoxydoxorubicin in advanced breast cancer**
R. P. Abratt, P. A. Willcox and *R. H. Hewitson*	1081	**Radical irradiation of localized inoperable lung cancer with concurrent chemotherapy and misonidazole: a phase I/II study**
Special Article		
EORTC Pharmacokinetics and Metabolism Group	1083	**Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelines**
Software Survey Section	I	

NUMBER 8, AUGUST 1987

Perspectives and Commentaries		
A. Gerard and *H. Bleiberg*	1089	**Delay in diagnosis of colorectal cancer**
J. P. Sculier, J. J. Body, D. Jacobowitz and *J. Fruhling*	1091	**Value of CEA determination in biological fluids and tissues**
L. Debusscher and *P. Stryckmans*	1095	**Perspectives in the treatment of hairy cell leukemia**
G. Boccuzzi, E. Brignardello, M. Massobrio and *L. Bonino*	1099	**Breast duct fluid dehydroepiandrosterone sulphate in fibrocystic disease**
Y. Horn, P. J. Schechter and *L. J. Marton*	1103	**Phase I–II clinical trial with alpha-difluoromethylornithine—an inhibitor of polyamine biosynthesis**
P. Sonneveld, E. Kokenberg, K. van der Steuijt and *K. Nooter*	1109	**Kinetics of daunomycin in leukemia cells and leukocytes *in vivo* in the rat**
S. W. J. Lamberts and T. Verleun	1117	**Differences in the mechanism of the inhibitory actions of catecholestrogens, tamoxifen and high concentrations of estrogens on prolactin release by cultured rat pituitary tumor cells**
M. van der Weide, M. M. A. C. Langenhuijsen, P. C. Huijgens, L. M. F. M. Imandt, F. C. de Waal, J. J. Mol, D. J. van Rhenen and *A. P. M. Kester*	1125	**Relation between leukaemic cell count and degree of maturation in acute myeloid leukaemia**

R. L. H. Jansen, M. E. L. van der Burg, J. Verweij and *G. Stoter*	1131	**Cyclophosphamide, hexamethylmelamine, adriamycin and cisplatin combination chemotherapy in mixed mesodermal sarcoma of the female genital tract**
W. A. Schroyens, P. F. Dodion, C. Sanders, M. Loos, N. E. Dethier, A. R. Delforge, P. A. Stryckmans and *Y. Kenis*	1135	***In vitro* chemosensitivity testing of flavone acetic acid (LM975; NSC 347512) and its diethylaminoethyl ester derivative (LM985; NSC 293015)**
S. Barni, P. Lissoni, F. Paolorossi, S. Crispino, F. Rovelli, L. Ferri, A. Sormani, U. D'Alonso, A. Bugatti, V. Nociti and *G. Tancini*	1141	**Effects of radical mastectomy on prolactin blood levels in patients with breast cancer**
P. Lelieveld, W. J. F. van der Vijgh and *D. van Velzen*	1147	**Preclinical toxicology of platinum analogues in dogs**
M. F. Spittle, B. T. Hill, M. J. Ostrowski, K. D. Macrae, T. D. Bates, W. M. C. Martin, N. T. Nicol and *G. A. Edelstyn*✠	1155	**A randomized, prospective, comparative, multicentre trial of a single combination versus alternating combinations of antitumour drugs in advanced breast cancer**
E. A. Tueni, P. Dumont, D. Jacobovitz, G. Atassi, P. Rocmans, F. Lejeune, P. de Franquen, P. Semal and *J. Klastersky*	1163	**Subrenal capsule assay for fresh human tumors in immunocompetent mice; an inappropriate technique for non-small cell lung cancer**
M. R. Price, G. Crocker, S. Edwards, I. S. Nagra, R. A. Robins, M. Williams, R. W. Blamey, D. M. Swallow and *R. W. Baldwin*	1169	**Identification of a monoclonal antibody-defined breast carcinoma antigen in body fluids**
A. E. van den Berg-Blok and *H. S. Reinhold*	1177	**Experimental hyperthermic treatment of a human colon carcinoma xenograft. The thermal sensitivity of the tumour microcirculation**
J.-P. Marie, C. Choquet, J.-Y. Perrot, D. Thevenin, C. Pillier, C. Boucheix and *R. Zittoun*	1181	***In vitro* depletion of clonogenic cells in adult acute lymphoblastic leukemia with a CD10 (anti-cALLA) monoclonal antibody**
C. K. Osborne, E. B. Coronado and *J. P. Robinson*	1189	**Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy**
M. Wolf, K. Havemann, R. Holle, V. Harms, P. Drings, K. Hans, H. Dombrowski and *N. Victor*	1197	**The prognostic value of response to the first cycle of chemotherapy in small cell lung cancer. Results of a multicenter German trial**
Clinical Trials Summaries		
P. E. Postmus, N. H. Mulder, J. C. V. D. Grampel, W. H. Meyers and *H. H. Berendsen*	1207	**Phase II evaluation of *trans*-$N_3P_3Az_2(NHMe)_4$ (AZP) in non-small cell lung cancer**
Letters to the Editor		
G. P. Smith, S. B. Calveley, M. J. Smith and *B. C. Baguley*	1209	**Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours**
G. Morpurgo and *M. Maggini*	1213	**A hypothesis on the etiology of malignant melanoma: the role of chemicals interfering with melanin synthesis**
J. Morère, C. Boaziz and *L. Israel*	1217	**Implantable infusion system and thoracic venous thromboses**
M. Sawada, M. Ozaki, Y. Mori, H. Taniguchi, R. Tateishi and *A. Wada*	1219	**Establishment of human ovarian tumour lines in nude mice and their responses to platinum analogues**
A. C. Perkins, M. V. Pimm and *R. W. Baldwin*	1225	**Demonstration of the hepatic uptake of radiolabelled immunotoxins using gamma scintigraphy**
Symposium Abstracts	1229	**Medical Management of Prostate Cancer. A Satellite Symposium of the 3rd International Congress on Hormones and Cancer**
Announcements	1253	
Books Received	1255	
Erratum	1256	
Software Survey Section	I	

List of Contents

NUMBER 9, SEPTEMBER 1987

Perspectives and Commentaries

R. L. Nutter and *J. D. Kettering*	1257	**Leukocyte adherence inhibition: history, biological basis and clinical usefulness**
P. Y. Holoye	1261	**Priming: theory or fact?**
Y.-T. M. Lee	1265	**The rationale for intra-arterial chemotherapy**
R. B. Lichtner and *G. L. Nicolson*	1269	**The pyrimido-pyrimidine derivatives RA 233 and RX-RA 85 affect growth and cytoskeletal organization of rat mammary adenocarcinoma cells**
S. Bogger-Goren, T. Gotlieb-Stematsky, M. Rachima, E. Barkowsky and *J. Schlomo-David*	1277	**Nasopharyngeal carcinoma in Israel: epidemiology and Epstein–Barr virus-related serology**
A. A. Miller, E. Kurschel, R. Osieka and *C. G. Schmidt*	1283	**Clinical pharmacology of sodium butyrate in patients with acute leukemia**
A. Pinelli, S. Trivulzio, D. D. von Hoff and *L. E. Warfel*	1289	**Cytotoxic effects and physicochemical properties of marycin: a new hematoporphyrin derivative**
S. Nagaoka, S. Kawasaki, Y. Karino, K. Sasaki and *T. Nakanishi*	1297	**Modification of cellular efflux and cytotoxicity of adriamycin by bisco-claulin alkaloid *in vitro***
C. Barone, A. Astone, C. Garufi, A. Grieco, A. Cavallaro, G. Netri, S. Rossi, A. Cassano, E. Ricevuto, M. R. Noviello and *G. Gambassi*	1303	**High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer**
J.-L. Formento, J.-L. Moll, M. Francoual, B. P. Krebs, G. Milano, N. Renee, R. Khater, M. Frenay and *M. Namer*	1307	**HPLC micromethod for simultaneous measurement of estradiol, progesterone, androgen and glucocorticoid receptor levels. Application to breast cancer biopsies**
D. J. Kerr, T. E. Wheldon, J. G. Russell, H. R. Maurer, A. T. Florence, G. W. Halbert, R. I. Freshney and *S. B. Kaye*	1315	**The effect of the non-ionic surfactant Brij 30 on the cytotoxicity of adriamycin in monolayer, spheroid and clonogenic culture systems**
C. Vagianos, M. Puntis, B. Jeppsson S. Steen, E. Zoucas and *S. Bengmark*	1323	**Increased uptake of 5-FU in experimental liver tumours by simultaneous infusion of norepinephrine**
N. K. Ahmed and *G. Vasanthakumar*	1329	**Characterization of daunorubicin resistance in K562 leukemia cells lacking daunorubicin reductase activity**
J. P. van Netten, I. G. Thornton, S. J. Carlyle, M. L. Brigden, P. Coy, N. L. Goodchild, S. Gallagher and *E. J. George*	1337	**Multiple microsample analysis of intratumor estrogen receptor distribution in breast cancers by a combined biochemical/immunohistochemical method**
A. Dees, J. Verweij, W. L. J. van Putten and *G. Stoter*	1343	**Mitomycin C is an inactive drug in the third-line treatment of hormone and chemotherapy refractory breast cancer**
J. Alexieva-Figusch, F. H. de Jong S. W. J. Lamberts, H. A. van Gilse and *J. G. M. Klijn*	1349	**Endocrine effects of aminoglutethimide plus hydrocortisone versus effects of high dose of hydrocortisone alone in postmenopausal metastatic breast cancer**
E. R. te Velde, J. D. F. Habbema, G. J. Gelpke and *R. E. Ballieux*	1357	**Prognostic significance of pretreatment variables in patients with invasive cervical cancer**
A. Jermy, J. S. Lilleyman, R. Jennings and *R. C. Rees*	1365	**Spontaneous natural killer cell activity in childhood acute lymphoblastic leukaemia**
A. Jermy, R. Jennings, J. S. Lilleyman and *R. C. Rees*	1371	**Immunomodulation of natural killer activity in children with acute lymphoblastic leukaemia**
S. A. D. Al-Ismail, J. A. Whittaker and *J. Gough*	1379	**Combination chemotherapy including epirubicin for the management of non-Hodgkin's lymphoma**
P. Boré, R. Bruno, N. Lena, R. Favre and *J. P. Cano*	1385	**Methotrexate and 7-hydroxy-methotrexate pharmacokinetics following intravenous bolus administration and high-dose infusion of methotrexate**
M. E. Gore, A. H. Calvert and *I. E. Smith*	1391	**High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study**
D. R. Newell, Z. H. Siddik, L. A. Gumbrell, F. E. Boxall, M. E. Gore, I. E. Smith and *A. H. Calvert*	1399	**Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin**

G. Giaccone, M. Donadio, G. Bonardi, M. Bagatella and *A. Calciati*	1407	**4'-Deoxydoxorubicin, an inactive drug in small cell lung cancer**
P. E. Postmus, H. H. Berendsen, N. van Zandwijk, T. A. W. Splinter, J. Th. M. Burghouts, W. Bakker and *the EORTC Lung Cancer Cooperative Group*	1409	**Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy**
Clinical Trials Summaries		
J. G. Rouëssé, A. T. van Oosterom, P. Capellaere, P. Kerbrat, C. J. van Coninge, D. Thomas and *D. Benshahar*	1413	**Phase II study of 1,2,4-triglycidyl urasol (TGU) in advanced soft tissue sarcoma. A trial of the EORTC Soft Tissue and Bone Sarcoma Cooperative Group**
Letters to the Editor		
C. J. Logothetis	1415	
A. Orfao, M. Gonzalez, J. F. San Miguel and *A. Lopez-Borrasca*	1417	**Expression of the FMC7 antigen in cases of B-lymphoproliferative diseases**
H. G. Drexler	1419	
Special Article		
B. G. Birkhead, E. M. Rankin, S. Gallivan, L. Dones and *R. D. Rubens*	1421	**A mathematical model of the development of drug resistance to cancer chemotherapy**
Announcement	1429	
EJCCO Service	i	
Software Survey Section	I	

NUMBER 10, OCTOBER 1987

Perspectives and Commentaries		
W. H. Mattheiem	1431	**Still less extensive surgery for breast cancer**
R. S. Foster Jr	1435	**Blood transfusions for surgical cancer patients: more harm than good?**
A. Verhest	1439	**A pathologist's view on how diagnostic material should be obtained**
Y. de Launoit, R. Kiss, A. Danguy and *R. Paridaens*	1443	**Effect of ovariectomy, hypophysectomy and/or GnRH analog (HRF) administration on the cell proliferation of the MXT mouse hormone-dependent mammary tumor**
G. Gasparini, L. Canobbio, E. Galligioni, T. Fassio, F. Brema, D. Crivellari, D. Villalta, G. di Fronzo, R. Talamini and *S. Monfardini*	1451	**Sequential combination of tamoxifen and high dose medroxyprogesterone acetate: therapeutic and endocrine effects in postmenopausal advanced breast cancer patients**
E. Tueni, N. Devleeschouwer, G. Leclercq, M. Nijs, A. Coune, A. Vermeulen and *R. Paridaens*	1461	**Endocrine effects of trilostane: *in vitro* and *in vivo* studies**
D. Fan, J. A. Ajani, F. L. Baker, B. Tomasovic, W. A. Brock and *G. Spitzer*	1469	**Comparison of antitumor activity of standard and investigational drugs at equivalent granulocyte–macrophage colony-forming cell inhibitory concentrations in the adhesive tumor cell culture system: an *in vitro* method of screening new drugs**
H. T. Mouridsen, L. Bastholt, R. Somers, A. Santoro, V. Bramwell, J. H. Mulder, A. T. van Oosterom, J. Buesa, H. M. Pinedo, D. Thomas and *R. Sylvester*	1477	**Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC soft tissue and bone sarcoma group**
S. Madani, J. Baillon, J. Fries, O. Belhadj, A. Bettaieb, M. B. Hamida and *G. Hervé*	1485	**Pyrimidine pathways enzymes in human tumors of brain and associated tissues: potentialities for the therapeutic use of *N*-(phosphonacetyl-L-aspartate and 1-β-D-arabinofuranosylcytosine**
E. L. Wynder and *L. S. Covey*	1491	**Epidemiologic patterns in lung cancer by histologic type**
G. A. R. Young, D. W. Hedley, C. A. Rugg and *H. J. Iland*	1497	**The prognostic significance of proliferative activity in poor histology non-Hodgkin's lymphoma: a flow cytometry study using archival material**

List of Contents

M. Fernö, A. Borg and *I. Idvall*	1505	**Estramustine binding site in human breast cancer biopsy samples. its relation to estrogen and progesterone receptor levels, age and menopausal status**
Y. Maehara, H. Kusumoto, H. Anai, T. Kusumoto, Y. Hiramoto and *K. Sugimachi*	1511	**1-Hexylcarbamoyl-5-fluorouracil is more cytostatic than 5-fluorouracil against human tumors *in vitro***
E. Curschellas, A. Matter and *U. Regenass*	1517	**Immunolocalization of cytoskeletal elements in human mammary epithelial cells**
L. S. Capolongo, G. Balconi, P. Ubezio, R. Giavazzi, G. Taraboletti, A. Regonesi, O. C. Yoder and *M. D'Incalci*	1529	**Antiproliferative properties of flavone acetic acid (NSC 347512) (LM 975), a new anticancer agent**
S. K. Singh, R. L. Marquet, D. L. Westbroek and *J. Jeekel*	1537	**Enhanced growth of artificial tumor metastases following blood transfusion: the effect of erythrocytes, leukocytes and plasma transfusion**
D. Y. Wang, B. L. de Stavola, R. D. Bulbrook, D. S. Allen, H. G. Kwa, A. A. Verstraeten, J. W. Moore, I. S. Fentiman, M. Chaudary, J. L. Hayward and *I. H. Gravelle*	1541	**The relationship between blood prolactin levels and risk of breast cancer in premenopausal women**
H. Abe, N. Ohya, K. F. Yamamoto, T. Shibuya, S. Arichi and *S. Odashima*	1549	**Effects of glycyrrhizin and glycyrrhetinic acid on growth and melanogenesis in cultured B16 melanoma cells**
J. Bártková, J. Burchell, J. Bártek, B. Vojtěšek, J. Taylor-Papadimitriou, A. Rejthar, Z. Stašková and *J. Kovařík*	1557	**Lack of β-casein production by human breast tumours revealed by monoclonal antibodies**
Clinical Trials Summaries		
M. Beer, F. Cavalli, S. B. Kaye, L. M. Lev, M. Clavel, J. Smyth, M. van Glabbeke, J. Renard and *H. M. Pinedo*	1565	**A phase II study of carboplatin in advanced or metastatic stomach cancer**
Announcements	1569	
Software Survey Section	I	

NUMBER 11, NOVEMBER 1987

L. Tomatis	1571	**An efficient primary prevention of cancer requires an integrated approach: Mühlbock Memorial Lecture**
Perspectives and Commentaries		
D. H. Johnson and *F. A. Greco*	1577	**Treatment of small cell lung cancer: another study on alternating chemotherapy**
R. Willemze	1581	**Recent developments in the early diagnosis of mycosis fungoides and Sézary's syndrome**
H. H. Hansen and *M. Hansen*	1585	**Tumor markers in small cell lung cancer**
M. D. Vincent, S. E. Ashley and *I. E. Smith*	1589	**Prognostic factors in small cell lung cancer: a simple prognostic index is better than conventional staging**
P. R. Harnett, M. H. N. Tattersall, A. S. Coates, R. van Couten and *J. Forbes*	1601	**Drug resistance in clinical practice: patterns of treatment failure in patients receiving systemic therapy for advanced breast cancer**
S. Einhorn, F. Vánky, D. Grandér and *J. S. Willems*	1607	**Induction of 2',5'-oligoadenylate synthetase in freshly separated malignant cells from solid tumors. Variability in the susceptibility of interferon**
V. J. Harvey, M. L. Slevin, S. P. Cheek, M. J. Barnett, W. Gregory, J. P. S. Thompson and *P. F. M. Wrigley*	1615	**A randomized trial comparing vindesine and cisplatinum to vindesine and methotrexate in advanced non small cell lung carcinoma**
C. L. Arteaga, D. L. Kisner, A. Goodman and *D. D. von Hoff*	1621	**Elliptinium, a DNA intercalating agent with broad antitumor activity in a human tumor cloning system**
A. Gouyette, A. Deniel, J.-L. Pico, J.-P. Droz, D. Baume, M. Ostronoff, N. le Bail and *M. Hayat*	1627	**Clinical pharmacology of high-dose etoposide associated with cisplatin. Pharmacokinetic and metabolic studies**
O. Wetter, D. Brandhorst and *W. Breipohl*	1633	**Differential immunocytological expression of a paraprotein-associated idiotype is possibly related to variant immunoglobulin molecules in plasmacytoma cells**

S. T. Milliken, M. H. N. Tattersall, R. L. Woods, A. S. Coates, J. A. Levi, R. M. Fox and *D. Raghavan*	1645	**Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens**
M. Bues-Charbit, J.-C. Gentet, J.-L. Bernard, V. Breant, J.-P. Cano and *C. Raybaud*	1649	**Continuous infusion of high-dose cisplatin in children: pharmacokinetics of free and total platinum**
J. Greidanus, E. G. E. de Vries, M. B. Nieweg, Z. J. de Langen and *P. H. B. Willemse*	1653	**Evaluation of a totally implanted venous access port and portable pump in a continuous chemotherapy infusion schedule on an outpatient basis**
A. Forbes, M. L. Wilkinson, M. J. Iqbal, P. J. Johnson and *R. Williams*	1659	**Response to cyproterone acetate treatment in primary hepatocellular carcinoma is related to fall in free 5α-dihydrotestosterone**
D. W. Beelen, K. Quabeck, H. K. Mahmoud, U. W. Schaefer, R. Becher, C. G. Schmidt, M. Bamberg, U. Quast, H. Grosse-Wilde, E. Haralambie, G. Linzenmeier, B. Stollmann, H. J. Richter, D. Hantschke, O. Thraenhardt, K.-B. Henneberg-Quester and *W. Luboldt*	1665	**Allogeneic bone marrow transplantation for acute leukaemia or chronic myeloid leukaemia in the fifth decade of life**
A. M. Carella, M. Martinengo, G. Santini, E. Gaozza, E. Damasio, D. Giordano, S. Nati, A. Congiu, R. Cerri, M. Risso, F. Ganzina and *A. M. Marmont*	1673	**Idarubicin in combination with etoposide and cytarabine in adult untreated acute non lymphoblastic leukemia**
M. R. Rossi, P. Banfi, M. Cappuccilli, V. Conter, D. de Poli, G. Piacentini, M. G. Zurlo and *G. Masera*	1679	**Prospective randomized comparison of two prophylactic regimens with trimethoprim–sulfamethoxazole in leukemic children: a two year study**
T. Mikulin and *J. D. Hardcastle*	1683	**Gastric cancer—delay in diagnosis and its causes**
B. Coiffier, A. Bosly, F. Caligaris-Cappio, C. Gisselbrecht, C. Patte, M. Schaadt and *M. Symann*	1691	**European School of Oncology: management of non-Hodgkin's lymphomas: conclusions of the European School of Oncology Meeting, 1986**
G. Giaccone, P. Ferrati, M. Donadio, F. Testore and *A. Calciati*	1697	**Reinduction chemotherapy in small cell lung cancer**
P. A. Philip, H. J. Rogers, R. R. Millis, R. D. Rubens and *R. A. Cartwright*	1701	**Acetylator status and its relationship to breast cancer and other diseases of the breast**
Clinical Trials Summaries		
S. Gundersen, S. Monfardini, G. Renard, M. van Glabbeke and *H. Pinedo*	1707	**Phase II trial of menogaril in advanced malignant melanoma. An EORTC trial**
Seminar Reports and Meeting Abstracts	1709	**IXth Meeting of the European Association for Cancer Research**
EJCCO Service	i	
Software Survey Section	I	

NUMBER 12, DECEMBER 1987

Perspectives and Commentaries		
P. Workman	1823	**TCNU: a ray of hope for designer nitrosoureas?**
R. Bataille and *J. Grenier*	1829	**Serum beta 2 microglobulin in multiple myeloma. A critical review**
P. Dodion	1833	**Chemotherapy in the elderly**
J. Vibe-Petersen, E. Bork, H. Møller and *H. H. Hansen*	1837	**A phase I clinical evaluation of 1-(2-chloroethyl)-3-[2-(dimethylaminosulphonyl)ethyl]-1-nitrosourea (TCNU)**
J. F. Smyth, J. S. Macpherson, P. S. Warrington, M. E. Kerr, J. M. Whelan, M. A. Cornbleet and *R. C. F. Leonard*	1845	**Phase I study of TCNU, a novel nitrosourea**
E. Walsh, H. Smyth and *M. McGuinness*	1851	**Release of malignancy-related fucopeptides from ascites tumour cells in association with membrane vesicles**
P. Klubes, S. Hiraga, R. L. Cysyk, E. S. Owens and *R. G. Blasberg*	1859	**Attempts to increase intratumoral blood flow in the rat solid Walker 256 tumor by the use of the perfluorocarbon emulsion Fluosol-DA**
G. J. Peters, E. Laurensse, A. Leyva and *H. M. Pinedo*	1869	**Purine nucleosides as cell-specific modulators of 5-fluorouracil metabolism and cytotoxicity**

S. B. Holmberg, L. Hafström and *G. Kjellberg*	1883	**RES function and tumour take and tumour growth in the liver and in the kidney—an experimental study in rats**
B. Hœrni, M. Trojani, H. Eghbali, F. Bonichon, J. M. Coindre, O. Garraud and *G. Hœrni-Simon*	1889	**Distinct entities among low-grade non-Hodgkin's malignant lymphomas. Analysis of a series of 377 cases**
C. J. Gallagher, F. Cairnduff and *I. E. Smith*	1895	**High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer**
P. Dodion, D. Bron, M. A. Mattelaer, M. Loos, A. Delforge, M. Rozencweig, P. Stryckmans and *Y. Kenis*	1901	**Sensitivity of normal human bone marrow myeloid progenitor cells to anthracycline, cisplatin, anthracene and flavone acetic acid derivatives, and its relevance for the prediction of human plasma concentrations of anticancer drugs**
P. Dodion, C. Sanders, W. Rombaut, M. A. Mattelaer, M. Rozencweig, P. Stryckmans and *Y. Kenis*	1909	**Effect of daunorubicin, carminomycin, idarubicin and 4-demethoxydaunorubicinol against human normal myeloid stem cells and human malignant cells *in vitro***
G. Valesini, V. Barnaba, R. Benvenuto, F. Balsano, P. Mazzanti and *P. Cazzola*	1915	**A calf thymus acid lysate improves clinical symptoms and T-cell defects in the early stages of HIV infection: second report**
R. Abele, M. Clavel, P. Dodion, U. Bruntsch, S. Gundersen, J. Smyth, J. Renard, M. van Glabbeke and *H. M. Pinedo*	1921	**The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas**
C. Kamby, C. Rose, B. Ejlertsen, J. Andersen, N. E. Birkler, L. Rytter, K. W. Andersen and *K. Zedeler*	1925	**Stage and pattern of metastases in patients with breast cancer**
W. V. Welshons and *V. C. Jordan*	1935	**Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture**
EJCCO Service	i	
Software Survey Section	I	
Volume Contents and Author Index for Volume 23 (1987)	iii	